BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JP...
January 03 2019 - 6:04AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
diseases, announced today that Chaim Lebovits, President and Chief
Executive Officer, will provide a corporate overview at the 2019
Biotech Showcase, being held on January 7-9, 2019 at the Hilton San
Francisco Union Square in San Francisco, California.
Ralph Kern M.D., MHSc, Brainstorm Chief
Operating Officer and Chief Medical Officer will also participate
in a panel discussion at the Sachs Associates 2nd Annual
Neuroscience Innovation Forum, taking place on Sunday, January 6,
2019, at the Marines’ Memorial Club in San Francisco.
2019 Biotech Showcase Presentation Details |
Date: |
|
Monday,
January 7, 2019 |
Time: |
|
11:00am
Pacific Time |
Location: |
|
Hilton San
Francisco Union Square, Yosemite A Ballroom |
Webcast: |
|
https://goo.gl/dD5YCN |
|
|
|
2nd Annual Neuroscience Innovation Forum
Details |
Date: |
|
Sunday,
January 6, 2019 |
Time: |
|
2:00pm
Pacific Time |
Location: |
|
Marines’
Memorial Club, SF |
Webcast: |
|
https://youtu.be/mVBXPFvRv9g |
Meetings
BrainStorm senior management will also be
hosting institutional investor and partnering meetings at the 2019
Biotech Showcase conference (https://goo.gl/SGFm62). Please use the
Investor contact information provided below to schedule a
meeting.
About NurOwn®
NurOwn® (MSC-NTF) cells represent a promising
investigational therapeutic approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can
effectively deliver multiple NTFs and immunomodulatory cytokines
directly to the site of damage to elicit a desired biological
effect and ultimately slow or stabilize disease progression.
BrainStorm is currently conducting a pivotal Phase 3 clinical trial
of autologous MSC-NTF cells for the treatment of amyotrophic
lateral sclerosis (ALS). BrainStorm has also recently received U.S.
FDA acceptance to initiate a Phase 2 trial in progressive Multiple
Sclerosis (MS) and plans to start enrollment in early 2019.
About BrainStorm Cell Therapeutics
Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
Safe-Harbor
Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone:
+1.215.485.6797Email: JP@brainstorm-cell.com
Investors:Marcy Beth NanusSolebury TroutPhone:
+1.646.378.2927Email: MNanus@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024